Literature DB >> 11487271

Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer.

M Sidiropoulos1, A Chang, K Jung, E P Diamandis.   

Abstract

Prostate androgen regulated transcript 1 (PART-1), is a gene predominantly expressed in the prostate gland and is regulated by androgens in human prostate cancer cell lines. Here, we report additional characteristics of PART-1 tissue expression and hormonal regulation and study its expression profile in human normal and matched prostate cancer tissues. Since PART-1 shows similarity to prostate-specific antigen (PSA) in prostate specificity and regulation, we hypothesized that it may be implicated in prostate carcinogenesis or may be a potential new biomarker. We used reverse transcriptase polymerase chain reaction (RT-PCR) to further characterize PART-1 tissue expression and hormonal regulation in the LNCaP prostate cancer cell line. RT-PCR analysis revealed that PART-1 is expressed not only in the prostate and salivary gland, but also in other tissues, including the thymus and placenta. In addition to androgen stimulation, PART-1 is also up-regulated by progestins, oestrogens and glucocorticoids. We further studied the expression of PART-1 in 27 paired (from the same patient) cancerous and non-cancerous prostatic tissues, with qualitative and quantitative RT-PCR (LightCycler technology), in order to examine whether PART-1 is overexpressed or underexpressed in cancer. Our results indicated that PART-1 is more frequently overexpressed in the cancerous prostatic tissue. We conclude that this gene is overexpressed in prostate cancer and may represent a novel prostate cancer tumour marker. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11487271      PMCID: PMC2364080          DOI: 10.1054/bjoc.2001.1883

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.

Authors:  A Magklara; A Scorilas; W J Catalona; E P Diamandis
Journal:  Clin Chem       Date:  1999-11       Impact factor: 8.327

2.  Factors influencing use of the prostate-specific antigen screening test in primary care.

Authors:  W P Moran; S J Cohen; J S Preisser; J L Wofford; B J Shelton; M W McClatchey
Journal:  Am J Manag Care       Date:  2000-03       Impact factor: 2.229

Review 3.  Prostate-specific antigen: a cancer fighter and a valuable messenger?

Authors:  E P Diamandis
Journal:  Clin Chem       Date:  2000-07       Impact factor: 8.327

4.  Urological cancers: do early detection strategies exist?

Authors:  V Webb; A Holmes
Journal:  BJU Int       Date:  2000-12       Impact factor: 5.588

5.  Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors.

Authors:  S McDonald; L Brive; D B Agus; H I Scher; K R Ely
Journal:  Cancer Res       Date:  2000-05-01       Impact factor: 12.701

6.  Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue.

Authors:  A Magklara; A Scorilas; C Stephan; G O Kristiansen; S Hauptmann; K Jung; E P Diamandis
Journal:  Urology       Date:  2000-09-01       Impact factor: 2.649

7.  Prostate cancer screening trends of New York State men at least 50 years of age, 1994 to 1997.

Authors:  K McDavid; T A Melnik; H Derderian
Journal:  Prev Med       Date:  2000-09       Impact factor: 4.018

Review 8.  The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast.

Authors:  M H Black; E P Diamandis
Journal:  Breast Cancer Res Treat       Date:  2000-01       Impact factor: 4.872

9.  Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.

Authors:  A Haese; C Becker; J Noldus; M Graefen; E Huland; H Huland; H Lilja
Journal:  J Urol       Date:  2000-05       Impact factor: 7.450

Review 10.  Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate.

Authors:  H G Rittenhouse; J A Finlay; S D Mikolajczyk; A W Partin
Journal:  Crit Rev Clin Lab Sci       Date:  1998-08       Impact factor: 6.250

View more
  11 in total

Review 1.  Long non‑coding RNA PART1: dual role in cancer.

Authors:  Rui Ran; Chao-Yang Gong; Zhi-Qiang Wang; Wen-Ming Zhou; Shun-Bai Zhang; Yong-Qiang Shi; Chun-Wei Ma; Hai-Hong Zhang
Journal:  Hum Cell       Date:  2022-07-21       Impact factor: 4.374

2.  PART1 expression is associated with poor prognosis and tumor recurrence in stage I-III non-small cell lung cancer.

Authors:  Ming Li; Weiwei Zhang; Shenjun Zhang; Changhui Wang; Yinping Lin
Journal:  J Cancer       Date:  2017-07-01       Impact factor: 4.207

3.  A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.

Authors:  Qian Zhao; Conghong Fan
Journal:  BMC Med Genet       Date:  2019-06-10       Impact factor: 2.103

4.  Downregulated Long Noncoding RNA PART1 Inhibits Proliferation and Promotes Apoptosis in Bladder Cancer.

Authors:  Xin Hu; Hefei Feng; Huaxing Huang; Wei Gu; Qiuyu Fang; Yi Xie; Chao Qin; Xiaowen Hu
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

5.  Inhibition of lncRNA PART1 Chemosensitizes Wild Type but Not KRAS Mutant NSCLC Cells.

Authors:  Shu-Chen Chen; Yu-Zhu Diao; Zi-Han Zhao; Xiao-Ling Li
Journal:  Cancer Manag Res       Date:  2020-06-10       Impact factor: 3.989

6.  Long non-coding RNA PART1 predicts a poor prognosis and promotes the malignant progression of pancreatic cancer by sponging miR-122.

Authors:  Xibao Hu; Lei Zhang; Jingjing Tian; Junhong Ma
Journal:  World J Surg Oncol       Date:  2021-04-17       Impact factor: 2.754

7.  Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein.

Authors:  A Kiessling; S Stevanovic; S Füssel; B Weigle; M A Rieger; A Temme; E P Rieber; M Schmitz
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

8.  The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells.

Authors:  D J P Henderson; A Byrne; K Dulla; G Jenster; R Hoffmann; G S Baillie; M D Houslay
Journal:  Br J Cancer       Date:  2014-02-11       Impact factor: 7.640

9.  Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.

Authors:  René Böttcher; Kalyan Dulla; Dianne van Strijp; Natasja Dits; Esther I Verhoef; George S Baillie; Geert J L H van Leenders; Miles D Houslay; Guido Jenster; Ralf Hoffmann
Journal:  Oncotarget       Date:  2016-10-25

10.  Long noncoding RNA MALAT1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12.

Authors:  Dong Xue; Hao Lu; Han-Yan Xu; Cui-Xing Zhou; Xiao-Zhou He
Journal:  J Cell Mol Med       Date:  2018-04-06       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.